Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.02M Buy
5,577
+11
+0.2% +$3.77K 0.17% 70
2026
Q1
$1.96M Buy
5,566
+15
+0.3% +$5.35K 0.19% 67
2025
Q4
$1.82M Buy
5,551
+6
+0.1% +$1.9K 0.17% 67
2025
Q3
$1.56M Buy
5,545
+11
+0.2% +$3.19K 0.15% 77
2025
Q2
$1.55M Buy
5,534
+381
+7% +$108K 0.17% 70
2025
Q1
$1.61M Sell
5,153
-30
-0.6% -$8.86K 0.19% 68
2024
Q4
$1.35M Sell
5,183
-23
-0.4% -$6.82K 0.16% 79
2024
Q3
$1.68M Buy
5,206
+14
+0.3% +$4.58K 0.21% 65
2024
Q2
$1.48M Hold
5,192
0.21% 63
2024
Q1
$1.48M Buy
5,192
+204
+4% +$59.7K 0.21% 64
2023
Q4
$1.44M Buy
4,988
+18
+0.4% +$4.9K 0.22% 68
2023
Q3
$1.34M Buy
+4,970
New +$1.24M 0.23% 70

Other funds holding AMGN

Compass Ion Advisors's AMGN Position: Q2 2026 in Review

Compass Ion Advisors increased its Amgen (AMGN) stake by 0.2% in Q2 2026, buying an estimated $3.77K and bringing the position to 5,577 shares worth $2.02M. The position accounts for 0.17% of the portfolio, ranked #70.

Compass Ion Advisors first reported a position in AMGN in Q3 2023 and has held it in 12 quarters since. 3,157 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Compass Ion Advisors held 5,577 shares of Amgen worth $2.02M as of Q2 2026.
  • Compass Ion Advisors bought 11 Amgen shares in Q2 2026, an estimated $3.77K.
  • Amgen made up 0.17% of Compass Ion Advisors's portfolio in Q2 2026, its #70 holding.
  • Compass Ion Advisors first reported a position in Amgen in Q3 2023 and has held it in 12 quarters since.
  • 3,157 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Compass Ion Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.